ARTICLE IN PRESSESMOGOOO SCIENCEANNALSOFBETTER MEDICINEBEST PRACTICEONCOLOGYhuuo noaon i oncoloSPECAL ARTICLENon-oncogene-addicted metastatic non-small-cell lung cancer:ESMOClinical Practice Guideline for diagnosis,treatment and follow-upLE.Hendriks,K.M.Kerr2,J.Menis,T.S.Mok,U.Nestles.6,A.Passaro,S.Peters,D.Planchard,E.F.Smit01B.J.Solomon12,G.Veronesi314&M.Reck5,on behalf of the ESMO Guidelines CommitteeDepartment of Pulmonology,GROW School for Oncology and Reproduction,Maastricht University Medical Center,Maastricht,The Netherlands;Aberdeen RoyalInfirmary,Aberdeen University Medical School,Aberdeen,UK;3Medical Oncology Department,University and Hospital Trust of Verona,Verona,Italy;+Department ofCinical Oncology,The Chinese University of Hong Kong,Prince of Wales Hospital,Hong Kong,China;SDepartment of Radiation Oncology,University Hospital Freiburg,Freiburg;Department of Radiation Oncology,Kliniken Maria Hilf,Moenchengladbach,Germany;Division of Thoracic Oncology,European Institute of Oncology IRCCS,Milan,Italy;Department of Oncology,Centre Hospitalier Universitaire Vaudois,Lausanne University,Lausanne,Switzerland;Department of Medical Oncology,Thoracic Group,Gustave-Roussy,Villejuif,France;Thoracic Oncology Service,Netherlands Cancer Institute,Amsterdam;Department of Pulmonary Diseases,LeidenUniversity Medical Center,Leiden,The Netherlands;Department of Medical Oncology,Peter MacCallum Cancer Centre,Melbourne,Australia;3Faculty of Medicineand Surgery-Vita-Salute San Raffaele University,Milan;Division of Thoracic Surgery,IRCCS San Raffaele Scientific Institute,Milan,Italy;5Department of ThoracicOncology,Airway Research Center North,German Center for Lung Research,Lung Clinic,Grosshansdorf,GermanyAvailable online XXXKey words:ESCAT,ESMO Clinical Practice Guideline (CPG),ESMO-MCBS,non-oncogene-addicted metastatic non-small-cell lung cancer(mNSCLC),treatment,targeted therapy,immunotherapyINCIDENCE AND EPIDEMIOLOGYmetastatic sites.Systematic collaboration and frequentDetails on incidence and epidemiology are covered in thecommunication between pathologists and interventionalistsSupplementary Material Section 1,available at https://doi.are recommended to maximise diagnostic yield of samples,org/10.1016/j.annonc.2022.12.013.e.g.rapid onsite evaluation of samples.Pathological diagnosis and subtyping are carried out ac-cording to the World Health Organization (WHO)guidelinesDIAGNOSIS,PATHOLOGY AND MOLECULAR BIOLOGY(2021).Terminology specifically for use when diagnosingDiagnostic proceduressmall samples is given in Table 1.Biopsy site,clinical infor-Details on diagnostic procedures are covered in themation and tumour morphology should allow for primarySupplementary Material Section 2,available at https://doi.lung cancer to be appropriately diagnosed in most cases.org/10.1016/小.annonc.2022.12.013.Clinical information is vital to prevent waste of limited tumourtissue in inappropriate pursuit of alternative,non-pulmonaryorigins of a tumour.This and other t
